Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesReimbursement/Payment Policymedical mutual - ohio Mycapssa Prior Auth Coverage…
    Ask Trek AI about this page
    Currentmedical mutual - ohioPolicy N/A

    Mycapssa (octreotide) delayed-release capsules coverage

    Customize your policy alerts

    Sign up for all medical mutual - ohio policy alerts

    Know when medical mutual - ohio releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines prior authorization recommendation, coverage criteria, and approval durations for Mycapssa (oral octreotide) for treatment of acromegaly in adults who have responded to and tolerated injectable somatostatin analogs, for Medical Mutual - Ohio pharmacy benefit.

    Policy Summary
    Payermedical mutual - ohio
    PolicyMycapssa (octreotide) delayed-release capsules coverage
    Policy CodePolicy N/A
    Change TypeAnnual review — no material changes
    Effective DateApr 16, 2026
    Last ReviewApr 16, 2026
    Next Review DateApr 16, 2026
    Key ActionPrior authorization recommended; initial approval requires prescription by or in consultation with an endocrinologist.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    18+Minimum age
    730dLookback (initial)
    130dLookback (continuing)
    1 yrInitial approval

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    1 yr
    Extended approval

    Coverage Criteria for Mycapssa (octreotide)

    Recommended Authorization Criteria — Acromegaly

    Coverage of Mycapssa is recommended when all of the following are met for acromegaly:

    ALL of the following

    • ALL of the following

      • Diagnosis of acromegaly (ICD-10 E22.0) when available for automation

        ICD-10 code used for automation

    • ALL of the following

      • Medication prescribed by or in consultation with an endocrinologist
    • ALL of the following

      • Patient has previously responded to and tolerated treatment with octreotide or lanreotide
    • ALL of the following

      • Baseline (prior to initiation of any somatostatin analog, dopamine agonist, or Somavert) IGF-1 level above the upper limit of normal for age and gender per lab reference
    • ALL of the following

      • Patient is at least 18 years of age

    Coding and Lookback Windows

    Diagnosis code required for automationICD-10Covered
    E22.0Acromegaly
    Lookback — prior octreotide/lanreotide/other somatostatin analog use
    Lookback window for octreotide/lanreotide/other somatostatin analogs730 days
    PurposeUsed for automation of approval for initial users who have prior exposure to injectable somatostatin analogs
    Applies toAny octreotide product (Bynfezia Pen, Sandostatin, Sandostatin LAR), lanreotide (Somatuline Depot), or other somatostatin analogs (Signifor, Signifor LAR)
    Lookback — continuing Mycapssa users
    Lookback window for prior Mycapssa use130 days
    PurposeUsed for automation of approval for continuing Mycapssa users

    Prescriber, Prior Authorization, and Automation Rules

    Prior Authorization

    Prior authorization required; specialist prescriber for initial therapy

    Prior authorization is recommended for pharmacy benefit coverage of Mycapssa. Initial approvals must be prescribed by or in consultation with a physician who specializes in the condition being treated (e.g., an endocrinologist); reauthorization requires documentation of response to therapy when reauthorization is allowed.

    • Prior authorization recommended for Mycapssa pharmacy benefit coverage.
    • Initial approval requires prescription by or in consultation with a specialist in the treated condition (endocrinologist).
    • If reauthorization is allowed, a response to therapy is required for continuation unless otherwise noted.
    Note

    Use automation when diagnosis, age, and prior-treatment lookback criteria are met

    Automation may be used to approve requests when the specified diagnosis, age, and prior-treatment history are documented. For initial users automation requires documentation of ICD-10 E22.0, age ≥18, and a history of any octreotide, lanreotide, or other somatostatin analog within the previous 730 days. For continuing users automation requires ICD-10 E22.0, age ≥18, and history of Mycapssa use within the last 130 days.

    Drug Definition

    Mycapssa (octreotide) delayed‑release capsules — definition and context
    Drug name and formulationMycapssa (octreotide) delayed‑release capsules, oral somatostatin analog
    IndicationLong-term maintenance treatment of acromegaly in patients who have responded to and tolerated octreotide or lanreotide
    Prior treatment noteIncludes patients who have responded to and tolerated subcutaneous Sandostatin injections
    Coverage contextPrior authorization recommended for pharmacy benefit; automation criteria use diagnosis code E22.0 and lookback windows

    Initial Therapy — Approval Criteria and Duration

    Initial Therapy

    Initial approval criteria and duration:

    ALL of the following

    • ALL of the following

      • ICD-10 code E22.0 confirming diagnosis of acromegaly
      • Patient is 18 years of age or older
      • History of any octreotide product, lanreotide product, or other somatostatin analog within the previous 730 days

        Lookback window: 730 days

    ALL of the following

    Continuation / Reauthorization Criteria

    Continuation / Reauthorization

    Criteria for continuing therapy and automation for continuing users:

    ALL of the following

    • ICD-10 code E22.0 confirming diagnosis of acromegaly
    • Patient is 18 years of age or older
    • History of Mycapssa use within the last 130 days may allow automation of approval for continuing users

      Lookback window: 130 days

    ALL of the following

    • If reauthorization is allowed, documentation of response to therapy is required for continuation unless otherwise noted
    Policy Summary
    Payermedical mutual - ohio
    PolicyMycapssa (octreotide) delayed-release capsules coverage
    Policy CodePolicy N/A
    Change TypeAnnual review — no material changes
    Effective DateApr 16, 2026
    Last ReviewApr 16, 2026
    Next Review DateApr 16, 2026
    Key ActionPrior authorization recommended; initial approval requires prescription by or in consultation with an endocrinologist.
    SourceLink
    On This Page
    Coverage Criteria for Mycapssa (octreotide)Coding and Lookback WindowsPrescriber, Prior Authorization, and Automation RulesDrug DefinitionInitial Therapy — Approval Criteria and DurationContinuation / Reauthorization Criteria
    Automation requirements paired with lookbackRequires ICD-10 E22.0 (acromegaly) and patient age ≥18 years
    • Initial user automation criteria: ICD-10 E22.0 (acromegaly), patient age 18 years or older, and history of any octreotide/lanreotide/other somatostatin analog within the prior 730 days.
    • Continuing user automation criteria: ICD-10 E22.0, patient age 18 years or older, and history of Mycapssa use within the last 130 days.
    Initial approval duration: 1 year

    ALL of the following

    • Extended approval duration: 1 year